Drug intelligence / Profile preview

metformin + entecavir

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy approach involving metformin as an add-on to entecavir treatment for chronic hepatitis B (CHB) infection. This combination was studied to potentially accelerate hepatitis B surface antigen (HBsAg) clearance, which would indicate functional cure of CHB. Metformin was hypothesized to have antiviral and immunomodulatory effects that could complement entecavir's action. However, clinical trials showed that while safe, metformin add-on therapy did not significantly accelerate HBsAg clearance compared to entecavir alone.

Other names: Metformin Add-on to EntecavirMetformin and Entecavir Combination

Targets

AMPK (Adenosine monophosphate–activated protein kinase)HBV Pol (Hepatitis B virus polymerase)CNT2 (Concentrative nucleoside transporter 2)SLC28A3 (Solute carrier family 28 member 3)OAT1 (Organic anion transporter 1)OCT2 (Organic cation transporter 2)

Beyond the preview

Go deeper on metformin + entecavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metformin + entecavir.